Aurinia Pharmaceuticals Inc

AUPHNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
16.13 USD
↗ 0.94 (6.19%)AT CLOSE (11:59 AM EDT)
16.11
↘ 0.02 (0.12%)
POST MARKET (AS OF 07:46 PM EDT)
Post Market
AS OF 07:46 PM EDT
16.11
↘ 0.02 (0.12%)
🔴Market: CLOSED

Aurinia Pharmaceuticals Inc (AUPH) is currently trading at $16.13. The stock presents a bullish profile across the board: both technical indicators and our fundamental models signal a "Strong Buy" and "Buy" respectively. Notable factors include a robust Altman Z-Score, exceptional Return on Equity (52.5%) and a bullish Golden Cross on the moving averages. Valuation metrics place AUPH at a fair price relative to peers.

Technical & fundamental data as of Aug 6, 2026.

Open?$15.93
High?$16.35
Low?$15.70
Prev. Close?$15.19
Volume?2.2M
Avg. Volume?1.6M
VWAP?$16.05
Rel. Volume?1.37x
Bid / Ask
Bid?$13.42 × 100
Ask?$18.54 × 100
Spread?$5.12
Midpoint?$15.98
Valuation & Ratios
Market Cap?2.0B
Shares Out?128.6M
Float?103.0M
Float %?79.2%
P/E Ratio?6.55
P/B Ratio?3.44
EPS?$2.32
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
128
Market Cap
2.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.auriniapharma.com
Listed
2009-10-21
Address
#140, 14315 - 118 AVENUE
EDMONTON, A0 T5L 4S6
Phone: 250-744-2487
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
100
Momentum?
73
Short Sent.?
60
Piotroski F-Score?6/9Mixed
Altman Z-Score?7.88Safe
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.44%Elevated
Short Interest?9.7M
Days to Cover?5.8
Free Float103.0M
Avg Daily Volume1.7M
Settlement Date2026-07-15
Financial Health
Current Ratio?5.55Strong
Quick Ratio?5.01Strong
Cash Ratio?0.47Low
Debt/Equity?0.11Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
72/100
P/E?
Peers
100
S&P
97
6.6CHEAP▾
P/B?
Peers
100
S&P
49
3.44FAIR▾
P/S?
Peers
100
S&P
19
6.55FAIR▾
P/FCF?
Peers
100
S&P
84
11.7CHEAP▾
EV/EBITDA?
Peers
100
S&P
49
15.2FAIR▾
EV/Sales?
Peers
100
S&P
23
6.63HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
91
52.5%STRONG▾
ROA?
Peers
50
S&P
97
41.2%STRONG▾
Cash Flow & Enterprise
FCF?$166.6M
Enterprise Value?$2.0B
Fundamentals ratios updated end of day
MarketsMoversWatchlist